Cargando…

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

BACKGROUND: A nonavalent human papillomavirus (HPV) vaccine has been licensed for use in women and men up to age 45 years in the United States. The cost-effectiveness of HPV vaccination for women and men aged 30 to 45 years in the context of cervical cancer screening practice was evaluated to inform...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jane J., Simms, Kate T., Killen, James, Smith, Megan A., Burger, Emily A., Sy, Stephen, Regan, Catherine, Canfell, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951902/ https://www.ncbi.nlm.nih.gov/pubmed/33705382 http://dx.doi.org/10.1371/journal.pmed.1003534

Ejemplares similares

The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology
por: de Kok, Inge M. C. M., et al.
Publicado: (2020)

The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost‐effectiveness of human papillomavirus screening with self‐collection and digital registry support
por: Keane, Adam, et al.
Publicado: (2021)

Testing previous model predictions against new data on human papillomavirus vaccination program outcomes
por: Smith, Megan A, et al.
Publicado: (2014)

Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia
por: Simms, Kate T., et al.
Publicado: (2017)

Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention
por: Jamieson, Lisa, et al.
Publicado: (2018)

Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017–2035: Example from Australia
por: Hall, Michaela T., et al.
Publicado: (2018)

Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand
por: Lew, Jie-Bin, et al.
Publicado: (2016)

Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway
por: Burger, E A, et al.
Publicado: (2012)

The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: A modelling study
por: Hall, Michaela T., et al.
Publicado: (2020)

Health services costs for cancer care in Australia: Estimates from the 45 and Up Study
por: Goldsbury, David E., et al.
Publicado: (2018)

Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries
por: Canfell, Karen, et al.
Publicado: (2020)

Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study
por: Legood, Rosa, et al.
Publicado: (2012)

Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis
por: Prem, Kiesha, et al.
Publicado: (2023)

A modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination
por: Velentzis, Louiza S, et al.
Publicado: (2023)

Cost-effectiveness of Human Papillomavirus Vaccination in the United States
por: Chesson, Harrell W., et al.
Publicado: (2008)

A model-based analysis of the health impacts of COVID-19 disruptions to primary cervical screening by time since last screen for current and future disruptions
por: Burger, Emily A, et al.
Publicado: (2022)

Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand
por: Simonella, Leonardo M, et al.
Publicado: (2013)

Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study
por: Goldsbury, David E., et al.
Publicado: (2020)

The healthcare costs of treating human papillomavirus-related cancers in Norway
por: Hylin, Hannah, et al.
Publicado: (2019)

Health services costs for ovarian cancer in Australia: Estimates from the 45 and Up Study
por: Goldsbury, David E., et al.
Publicado: (2023)

Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use
por: Smith, Megan A., et al.
Publicado: (2016)

Health impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptions
por: Burger, Emily A., et al.
Publicado: (2022)

Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries
por: Brisson, Marc, et al.
Publicado: (2020)

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States
por: Kim, Jane J, et al.
Publicado: (2009)

Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country
por: Burger, Emily A., et al.
Publicado: (2018)

The predicted impact and cost‐effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome
por: Kang, Yoon‐Jung, et al.
Publicado: (2019)

Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study
por: Velentzis, Louiza S, et al.
Publicado: (2014)

Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis
por: Smith, Megan A., et al.
Publicado: (2021)

Development and application of a framework to estimate health care costs in China: The cervical cancer example
por: Liu, Yi-Jun, et al.
Publicado: (2019)

Incremental Benefits of Male HPV Vaccination: Accounting for Inequality in Population Uptake
por: Smith, Megan A., et al.
Publicado: (2014)

Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia
por: Smith, Megan A., et al.
Publicado: (2017)

Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys
por: Burger, Emily A., et al.
Publicado: (2014)

National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study
por: Smith, Megan A, et al.
Publicado: (2022)

Alcohol consumption, drinking patterns and cancer incidence in an Australian cohort of 226,162 participants aged 45 years and over
por: Sarich, Peter, et al.
Publicado: (2020)

HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control
por: Canfell, Karen, et al.
Publicado: (2019)

Trends in Human Papillomavirus–Associated Cancers — United States, 1999–2015
por: Van Dyne, Elizabeth A., et al.
Publicado: (2018)

Human Papillomavirus–Attributable Cancers — United States, 2012–2016
por: Senkomago, Virginia, et al.
Publicado: (2019)

Cost-effectiveness of cervical cancer screening with primary HPV testing for unvaccinated women in Sweden
por: Fogelberg, Sara, et al.
Publicado: (2020)

Prevalence of Human Papillomavirus in 45 Greek Patients with Oral Cancer
por: Kouvousi, Maria, et al.
Publicado: (2013)

Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program
por: Pearson, Amber L, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vbbr8burlqa01hdl198ivm7vr6